clinical trial · NCT07218341
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Eli Lilly and Company·phase4·recruiting·n = 150
Chronic Lymphocytic LeukemiaLymphoma, Small LymphocyticPirtobrutinibIdelalisib
brief summary
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.
started
Mar 9, 2026
primary completion
May 1, 2030
completion
Dec 1, 2032
last updated
Apr 17, 2026
official title
Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-20020 With BTKi Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol